PF3D7_1459700

PF3D7_1459700 (PfPdx1) is the catalytic subunit of the de novo pyridoxal 5'-phosphate (PLP) synthase pathway that supplies vitamin B6 to blood-stage P. falciparum parasites (PMID:16339145). It condenses ribose 5-phosphate and glyceraldehyde 3-phosphate with ammonia through a series of imine bond formations to synthesize PLP, with the ammonia supplied by the glutaminase subunit PfPdx2; formation of the heteromeric PfPdx1–PfPdx2 complex is obligatory for the catalytic activity of either subunit (PMID:16339145, PMID:23039077). The C-terminal domain of PfPdx1 carries out four distinct steps — assembly of monomers into the dodecameric complex, binding of the pentose substrate ribose 5-phosphate, formation of the I320 reaction intermediate, and PLP synthesis — with only the final PLP-forming step conferred in trans, accounting for the cooperative behavior of the assembled complex (PMID:20837012). Species-specific structural features govern the Pdx1–Pdx2 interaction, since a chimeric complex of PfPdx1 with the bacterial Pdx2 ortholog YaaE forms but fails to reach full catalytic activity (PMID:16339145). The complex is a validated drug target: D-erythrose 4-phosphate inhibits PfPdx1 and its hydrazide analogue 4PEHz inhibits both the isolated enzyme and the heteromeric complex, with overexpression of PfPdx1/PfPdx2 protecting parasites, confirming the PLP synthase complex as the direct intracellular target (PMID:23039077).

1. 2005 High

   Established that PfPdx1 is the PLP synthase catalytic subunit and that it requires assembly with the glutaminase subunit PfPdx2 for any activity, defining the enzyme's obligate heteromeric architecture.

   Evidence Recombinant expression, in vitro activity assays, and co-complex reconstitution

   PMID:16339145

   Open questions at the time

   • Stoichiometry and higher-order oligomeric state of the intact complex not resolved here
   • Kinetic parameters of substrate turnover not quantified
2. 2005 Medium

   Tested whether the Pdx1–Pdx2 interface is species-specific by pairing PfPdx1 with the bacterial Pdx2 ortholog YaaE, showing the chimera assembles but does not reach full activity.

   Evidence In vivo and in vitro chimeric complex formation and activity measurement

   PMID:16339145

   Open questions at the time

   • Structural basis of the interface incompatibility not defined
   • Single lab, single ortholog pairing tested
3. 2005 Medium

   Demonstrated that blood-stage parasites express both PfPdx1 and PfPdx2, establishing that de novo vitamin B6 biosynthesis is operative at the clinically relevant stage.

   Evidence Expression profiling combined with recombinant biochemical characterization

   PMID:16339145

   Open questions at the time

   • Contribution of de novo synthesis versus salvage to parasite B6 pools not quantified
   • Stage-specific requirement not tested by genetic knockout
4. 2010 Medium

   Dissected the multifunctional C-terminus of PfPdx1, resolving how monomer assembly, R5P binding, intermediate formation, and PLP synthesis are partitioned and why only the final step acts in trans.

   Evidence C-terminal deletion analysis with enzyme activity assays and reaction-intermediate detection

   PMID:20837012

   Open questions at the time

   • Residue-level catalytic mechanism of the trans PLP-forming step not defined
   • No crystal structure of the assembled PfPdx1 dodecamer provided
5. 2013 Medium

   Defined the full condensation chemistry (ammonia + R5P + G3P via imine bonds) and identified E4P and its hydrazide analogue 4PEHz as inhibitors, opening a route to pharmacological targeting.

   Evidence In vitro enzyme inhibition assays, molecular docking, and transgenic overexpression lines

   PMID:23039077

   Open questions at the time

   • Inhibitor selectivity over host enzymes not established
   • IC50 values in the micromolar range leave potency to be improved
6. 2013 Medium

   Confirmed the PLP synthase complex as the direct intracellular target of 4PEHz by showing PfPdx1/PfPdx2 overexpression rescues parasites from the inhibitor.

   Evidence Transgenic parasite overexpression with in vitro growth inhibition assay

   PMID:23039077

   Open questions at the time

   • Whether inhibition is essential for parasite killing across all stages not tested
   • Single lab genetic rescue

• The in vivo essentiality of PfPdx1 by direct genetic knockout, its cellular localization, and the atomic structure of the assembled Plasmodium complex remain uncharacterized in the available corpus.
• No loss-of-function knockout establishing essentiality
• No subcellular localization data
• No high-resolution structure of the PfPdx1 dodecamer or PfPdx1–PfPdx2 complex